UNDERWRITING AGREEMENTUnderwriting Agreement • January 30th, 2023 • MDNA Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
COMMON STOCK PURCHASE WARRANT MDNA LIFE SCIENCES, INC.Common Stock Purchase • January 30th, 2023 • MDNA Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
This Warrant is being issued pursuant to that certain Securities Purchase Agreement dated as of December __, 2022 between the Holder and the Company (the “Securities Purchase Agreement”). In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Securities Purchase Agreement.
12% CONVERTIBLE PROMISSORY NOTE DUE JUNE 1, 2023MDNA Life Sciences, Inc. • January 30th, 2023 • In vitro & in vivo diagnostic substances • New York
THIS 12% CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued 12% Convertible Promissory Notes of MDNA Life Sciences, Inc., a Delaware corporation (the “Company”), having its principal place of business at 2054 Vista Parkway, Suite 400, West Palm Beach, FL 33411, designated as its 12% Convertible Promissory Notes due June 1, 2023 (this Note, the “Note” and, collectively with the other Notes of such series, the “Notes”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 30th, 2023 • MDNA Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December __, 2022, between MDNA Life Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
Executive Employment AgreementExecutive Employment Agreement • January 30th, 2023 • MDNA Life Sciences, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS AGREEMENT (“Agreement”) is made this 1st day of December, 2022 by and between MDNA Life Sciences, Inc., a Delaware corporation (the “Company”) and Jonathan Mills, an individual residing at 25 Hobart, Whitley Bay, Tyne & Wear, NE26 3TA, UK (Executive).
